CIK 0000879169
- Large accelerated filer
INCYTE CORP
Sign in to watch- Ticker
- INCY
- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943136539
- Phone
- +1 302-498-6700
- Business address
- 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803
- Former names
- INCYTE INC, INCYTE GENOMICS INC, INCYTE PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,285,604
- in 7 filings, $33.3M under 10b5-1 plans
Net −$33,285,604. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-16 | Stein Steven H CMO & Head of Late-Stage Dev. | Exercise or conversion 10b5-1 | +576 | $68.25 | $39K | 31,492 |
| 2026-11-16 | Stein Steven H CMO & Head of Late-Stage Dev. | Sale 10b5-1 | −576 | $121.98 | $70K | 30,916 |
| 2026-11-16 | Stein Steven H CMO & Head of Late-Stage Dev. | Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 | −576 | 20,146 | ||
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Exercise or conversion 10b5-1 | +455 | $61.18 | $28K | 183,655 |
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Exercise or conversion 10b5-1 | +422 | $61.76 | $26K | 184,077 |
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Exercise or conversion 10b5-1 | +926 | $64.25 | $59K | 185,003 |
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Exercise or conversion 10b5-1 | +839 | $71.93 | $60K | 185,842 |
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Sale 10b5-1 | −877 | $121.98 | $107K | 184,965 |
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Sale 10b5-1 | −1,765 | $120.46 | $213K | 183,200 |
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 | −455 | 3,641 | ||
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 | −422 | 3,380 | ||
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 | −926 | 18,505 | ||
| 2026-11-16 | CAGNONI PABLO J President, Global Head of R&D | Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 | −839 | 16,788 | ||
| 2026-11-13 | Heeson Lee EVP, Head of Incyte Intl | Sale 10b5-1 | −1,471 | $121.89 | $179K | 36,107 |
| 2026-11-13 | Heeson Lee EVP, Head of Incyte Intl | Sale 10b5-1 | −2,200 | $120.44 | $265K | 33,907 |
| 2026-11-13 | Heeson Lee EVP, Head of Incyte Intl | Sale 10b5-1 | −874 | $121.16 | $106K | 33,033 |
| 2026-11-13 | Heeson Lee EVP, Head of Incyte Intl | Sale 10b5-1 | −3,700 | $120.33 | $445K | 29,333 |
| 2026-11-13 | Heeson Lee EVP, Head of Incyte Intl | Sale 10b5-1 | −2,449 | $121.13 | $297K | 26,884 |
| 2026-11-06 | Stein Steven H CMO & Head of Late-Stage Dev. | Exercise or conversion 10b5-1 | +8,539 | $68.62 | $586K | 39,455 |
| 2026-11-06 | Stein Steven H CMO & Head of Late-Stage Dev. | Exercise or conversion 10b5-1 | +12,335 | $72.27 | $891K | 51,790 |
Page 1 of 35 · 681 trades